Science News
from research organizations

Axillary lymph node evaluation performed frequently in ductal carcinoma in situ

Date:
April 9, 2015
Source:
The JAMA Network Journals
Summary:
Axillary lymph node evaluation is performed frequently in women with ductal carcinoma in situ breast cancer, despite recommendations generally against such an assessment procedure in women with localized cancer undergoing breast-conserving surgery, according to a study.
Share:
FULL STORY

Axillary lymph node evaluation is performed frequently in women with ductal carcinoma in situ breast cancer, despite recommendations generally against such an assessment procedure in women with localized cancer undergoing breast-conserving surgery, according to a study published online by JAMA Oncology.

While axillary lymph node evaluation is the standard of care in the surgical management of invasive breast cancer, a benefit has not been demonstrated in ductal carcinoma in situ (DCIS). For women with invasive breast cancer, sentinel lymph node biopsy (SLNB) replaced full axillary lymph node dissection (ALND). The sentinel nodes are the first few lymph nodes into which a tumor drains.

Guidelines published by the American Society of Clinical Oncology and the National Comprehensive Cancer Network recommend against axillary evaluation in women undergoing breast-conserving surgery (BCS). If invasive cancer were to be discovered SLNB could be performed at a later date. But because a total mastectomy precludes future SLNB, the guidelines suggest SLNB may be appropriate for some high-risk patients because axillary evaluation would be indicated if invasive cancer was found, according to background in the study.

Dawn L. Hershman, M.D., M.S., of Columbia University Medical Center, New York, and coauthors determined the incidence of axillary lymph node evaluation in women with DCIS and identified factors associated with the procedure. The authors analyzed medical records from 2006 through 2012 for women with DCIS who had BCS or mastectomy. The study analysis included 35,591 women.

Of the women with DCIS, 26,580 (74.7 percent) had BCS and 9,011 (25.3 percent) underwent mastectomy. The authors found that 17.7 percent of the women who had BCS and 63 percent of those patients who underwent mastectomy had an axillary lymph node evaluation, according to the results. Among the 63 percent of women who had a mastectomy and underwent axillary evaluation, 15.2 percent of women had full ALND and 47.8 percent had SLNB. Among the 17.7 percent of women who had axillary evaluation with BCS, 16.7 percent of women underwent SLNB and only 1 percent had ALND.

Rates of axillary evaluation increased over time with mastectomy from 56.6 percent in 2006 to 67.4 percent in 2012, but the rates remained relatively stable with BCS with 18.5 percent in 2006 and 16.2 percent in 2012.

Factors such as having surgery at a nonteaching hospital in an urban area were associated with higher rates of axillary evaluation with mastectomy and increasing surgeon volume was associated with decreasing axillary evaluation among women undergoing BCS, the results also indicate.

"Despite uncertainty regarding the clinical benefit of axillary evaluation in women with DCIS, we found that 17.7 percent of women undergoing BCS and 63 percent of women undergoing mastectomy had either an SLNB or ALND. Though use of axillary evaluation in DCIS may be appropriate in some cases, the high rates of axillary evaluation indicate that additional research is needed in this area. In addition to better predictive tools for axillary involvement, other surgical approaches should be evaluated, such as placing a marker in the node rather than removing it, thus allowing for sentinel node removal at a second operation should invasive cancer be identified on final pathology. Perhaps most importantly, additional prospective evaluation is needed to determine if there is a clinical benefit to axillary evaluation in women with DCIS," the study concludes.


Story Source:

Materials provided by The JAMA Network Journals. Note: Content may be edited for style and length.


Journal Reference:

  1. Dawn L. Hershman, MD, MS et al. The Influence of Hospital and Surgeon Factors on the Prevalence of Axillary Lymph Node Evaluation in Ductal Carcinoma In Situ. JAMA Oncology, April 2015 DOI: 10.1001/jamaoncol.2015.0389

Cite This Page:

The JAMA Network Journals. "Axillary lymph node evaluation performed frequently in ductal carcinoma in situ." ScienceDaily. ScienceDaily, 9 April 2015. <www.sciencedaily.com/releases/2015/04/150409120257.htm>.
The JAMA Network Journals. (2015, April 9). Axillary lymph node evaluation performed frequently in ductal carcinoma in situ. ScienceDaily. Retrieved May 8, 2017 from www.sciencedaily.com/releases/2015/04/150409120257.htm
The JAMA Network Journals. "Axillary lymph node evaluation performed frequently in ductal carcinoma in situ." ScienceDaily. www.sciencedaily.com/releases/2015/04/150409120257.htm (accessed May 8, 2017).